Coronary artery disease risk among obese metabolically healthy young men

Gilad Twig1, Hertzel C Gerstein2, Dana Ben-Ami Shor2

  • 1Department of Medicine 'B'Dr. Pinchas Bornstein Talpiot Medical Leadership ProgramChaim Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, IsraelIsrael Defense Forces Medical CorpsRamat Gan, IsraelDivision of Endocrinology and MetabolismPopulation Healthy Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, CanadaSackler School of MedicineTel Aviv University, Tel Aviv, IsraelIsrael Ministry of HealthJerusalem, IsraelDepartment of EndocrinologyChaim Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, IsraelDivision of EndocrinologyDiabetes and Hypertension, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA Department of Medicine 'B'Dr. Pinchas Bornstein Talpiot Medical Leadership ProgramChaim Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, IsraelIsrael Defense Forces Medical CorpsRamat Gan, IsraelDivision of Endocrinology and MetabolismPopulation Healthy Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, CanadaSackler School of MedicineTel Aviv University, Tel Aviv, IsraelIsrael Ministry of HealthJerusalem, IsraelDepartment of EndocrinologyChaim Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, IsraelDivision of EndocrinologyDiabetes and Hypertension, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA Department of Medicine 'B'Dr. Pinchas Bornstein Talpiot Medical Leadership ProgramChaim Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, IsraelIsrael Defense Forces Medical CorpsRamat Gan, IsraelDivision of Endocrinology and MetabolismPopulation Healthy Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, CanadaSackler School of MedicineTel Aviv University, Tel Aviv, IsraelIsrael Ministry of HealthJerusalem, IsraelDepartment of EndocrinologyChaim Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, IsraelDivision of EndocrinologyDiabetes and Hypertension, Harvard Medical School, Brigham

Insights

Obese young men without metabolic risk factors still face increased coronary artery disease (CAD) risk. This study highlights that even metabolically healthy obesity elevates CAD risk in this demographic.

Area of Science:

  • Cardiology
  • Metabolic Health
  • Public Health

Background:

  • Obesity is a growing concern in young adults.
  • The link between obesity and cardiovascular disease is well-established.
  • However, the risk associated with metabolically healthy obesity (MHO) in young men is less understood.

Purpose of the Study:

  • To evaluate the association between MHO and incident coronary artery disease (CAD) in young men.
  • To determine if MHO confers an increased risk of CAD independent of traditional risk factors.

Main Methods:

  • A longitudinal cohort study of 31,684 young men from the MELANY cohort.
  • Participants were classified by Body Mass Index (BMI) and metabolic health status (Adult Treatment Panel-III criteria).
  • Cox proportional hazard models were used to assess CAD risk over a median follow-up of 6.1 years.

Main Results:

  • Metabolically healthy obesity (MHO) was identified in 1.9% of participants.
  • A significantly higher risk of incident CAD was observed in MH-obese men (HR=3.08) compared to metabolically healthy normal-weight men.
  • This association remained significant after adjusting for multiple CAD risk factors.

Conclusions:

  • Obesity may increase the risk of coronary artery disease in young men, even without other metabolic abnormalities.
  • Metabolically healthy obesity represents a significant risk factor for future cardiovascular events in young men.
  • These findings underscore the importance of weight management for cardiovascular health in young men.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
866
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.0K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
303
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
346
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
585